Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vaccines to treat H1N1 Swine and other Influenza viruses
Subscribe to our email newsletter
CEL-SCI has filed a provisional US patent application covering its LEAPS immune therapy drugs (vaccines). It is intended for the prevention/treatment of H1N1, swine flu, bird flu, Influenza A and/or evolving mutants or variants of these viruses.
The company is using conserved epitopes from essential proteins, found in the A influenza virus for H1N1, H1N5, swine, bird flu and Spanish influenza, to create an effective vaccine that could potentially fight against the virus.
The company said that it has initiated on these various methods of use and applications for the A influenza vaccines. These LEAPS vaccines are expected to induce antigen specific immune response which, based on other LEAPS animal tests in multiple disease models, may lead to a protective immune response.
Geert Kersten, CEO of CEL-SCI, said: By filing this provisional patent in the US, we are preserving our rights to file patents on these inventions and for their use world-wide either as an injected vaccine before a person is infected or exposed or as a therapeutic vaccine for treatment.